| Description | Cintirorgon (LYC-55716) is a selective, oral agonist of RORγ. Cintirorgon modulates gene expression of RORγ expressing T lymphocyte immune cells. |
| In vitro | 经口服给药后，Cintirorgon选择性地结合到核受体转录因子RORγ，形成一个受体复合物，该复合物转移至细胞核，并与ROR反应元件(ROREs)结合，增强了17型T细胞的功能、增殖和存活，包括Th17（辅助T细胞）和Tc17（细胞毒性T细胞）。RORγ是参与Th17/Tc17分化的核受体转录因子，对免疫激活起着关键作用。 |
| Synonyms | LYC-55716 |
| molecular weight | 603.53 |
| Molecular formula | C27H23F6NO6S |
| CAS | 2055536-64-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 110 mg/mL (182.26 mM) |
| References | 1. Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017. |